Skip to main content

Table 4 Headache-related endpoints

From: Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review

Headache-related endpoints

Number of studies present (%)

Migraine days

37 (80.4%) [38,39,40,41,42,43,44,45,46,47,48,49,50, 52,53,54,55,56,57,58,59, 62,63,64,65, 68,69,70, 72, 75,76,77,78, 80,81,82,83]

Acute treatment utilization

33 (71.7%) [38, 40,41,42,43,44, 47,48,49, 52,53,54,55, 57,58,59, 61, 62, 64,65,66,67,68,69,70,71, 77,78,79,80,81,82,83]

Headache days

31 (67.4%) [38, 39, 41, 43,44,45,46,47,48,49,50, 52,53,54,55,56,57, 60,61,62,63,64, 66, 67, 69,70,71,72, 74, 76, 80]

Intensity of headache

16 (34.8%) [38, 42,43,44, 52, 54, 57, 64, 68, 74, 76, 78,79,80, 82, 83]

Conversion of medication overuse to non-medication overuse

12 (26.1%) [40, 46, 47, 49, 51, 52, 60, 67, 72, 77, 79, 83]

Conversion to episodic migraine

10 (21.7%) [40, 41, 50, 62, 66, 74, 77, 79, 82, 83]

Moderate to severe headache days

4 (8.7%) [45, 61, 71, 79]

Crystal clear days

2 (4.3%) [61, 62]

Severe headache days

1 (2.2%) [63]